RxDoctor Payments Data

Thomas Kwiatkowski, MD

Neurology · Pittsfield, MANPI 1699758334

Payments from drug & device makers

$8,868in general payments, 2019–2025

Across 64 payments — averaging $138.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$7K
  • Lilly USA, LLC$409
  • Eisai Inc.$332
  • Novartis$275
  • AbbVie$233
  • Biogen$188
  • plus $293 from 4 others

What the payments were for

  • Consulting fees$5,75065%
  • Travel & lodging$1,24514%
  • Food & beverage$1,87321%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,868 in reported general payments places this provider in the 65th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$160,934
Medicare patients
912
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MayzentSiponimod50$456,942
TecfideraDimethyl Fumarate29$254,533
Kesimpta PenOfatumumab21$179,344
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5024$175,187
FingolimodFingolimod Hcl36$146,394
NuplazidPimavanserin Tartrate25$117,566
EpidiolexCannabidiol (Cbd)32$74,861
Glatiramer Acetate20$50,454
UbrelvyUbrogepant36$48,969
GlatopaGlatiramer Acetate19$43,472
Emgality PenGalcanezumab-Gnlm34$37,299
Nurtec OdtRimegepant Sulfate19$25,969
Tegretol XrCarbamazepine41$21,693
Lacosamide189$18,134
Lamotrigine ErLamotrigine13$16,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$275$456,94250 claims
BiogenTecfidera$188$254,53329 claims
AbbVieUbrelvy$233$48,96936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 761 neurology providers in Massachusetts.

Other neurology in Pittsfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →